ANN ARBOR, Mich., July 29, 2020 /PRNewswire/ — Strata Oncology, Inc. , a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with BioMed Valley Discoveries Inc.. to accelerate patient identification and enrollment for BioMed Valley’s Phase 2 study of BVD-523 (ulixertinib) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (non-BRAF V600E mutations).  Ulixertinib is a first-in-class potent and selective small molecule inhibitor of ERK1/2. BioMed Valley reported positive preliminary Phase I data for ulixertinib in patients harboring MAPK alterations, including atypical BRAF alterations.

Read more here.